Please login to the form below

Not currently logged in
Email:
Password:

Gilead works with Indian generic firms to improve HIV drug access

Collaboration with Mylan, Ranbaxy and Strides aims to reduce cost of emtricitabine

Gilead Sciences

Gilead have agreed to collaborate with generic firms Mylan, Ranbaxy and Strides to reduce manufacturing costs, accelerate access and improve availability of Gilead's HIV medicine emtricitabine (FTC) in developing countries.

This agreement includes single tablet regimens containing emtricitabine and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines.

Emtricitabine, which is marketed by Gilead under the brand name Emtriva, is recommended by World Health Organization (WHO), along with well tenofovir disoproxil fumarate (TDF), as the preferred components of first and second line HIV therapy.

The agreement will also see the India-based generic companies take over manufacturing of emtricitabine from Gilead, as well as fund process improvements to reduce manufacturing costs.

Within developing countries it is thought that there are around 3m people living with HIV/AIDS who are receiving medicine, and 2.7m of those receive a TDF-containing regime, a medicine originally developed by Gilead and that is now licensed to generic manufacturers.

However, it is estimated that around 7m people are still in need of treatment and are waiting for access to medicines, according to a special report from Médecins Sans Frontières.

By reducing costs and bringing manufacturing closer to developing nations, it is hoped that vital HIV/AIDS drugs will reach a greater number of those in need of treatment.

A total of thirteen Indian generic companies now have licensed Gilead HIV medicines through non-exclusive generic licensing agreements established with generic manufacturers.

Mylan CEO Heather Bresch commented that she was “delighted to be collaborating with Gilead” in an attempt to enable greater access to affordable medicine for HIV in developing countries.

6th August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Seven Stones

Seven Stones is a creative, independent healthcare communications agency focused on great work with a strong and effective ‘Media Neutral’...

Latest intelligence

The patient will see you now
GCI Health’s Laura Starr and Chris Bath report on how the dawning era of mobile tech and the ‘Internet of Things’ has transformed the health and wellness arena....
When forecasters take the floor: 6 tips on presenting a forecast
Peter Mansell queries some of pharma’s leading forecasters for their dos and don’ts on presenting a forecast...
Enablers of drug innovation could lie in the numbers
Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem....

Infographics